Arif Akyildiz, Betul Gok Yavuz, Rashad Ismayilov, Muge Buyukaksoy, Sena Sozen, Joe Ramzi Eid, Rony Avritscher, Lee Sunyoung, Suayib Yalcin, Ahmed O Kaseb
{"title":"经动脉化疗栓塞加全身治疗晚期肝癌的综合评价。","authors":"Arif Akyildiz, Betul Gok Yavuz, Rashad Ismayilov, Muge Buyukaksoy, Sena Sozen, Joe Ramzi Eid, Rony Avritscher, Lee Sunyoung, Suayib Yalcin, Ahmed O Kaseb","doi":"10.1007/s12029-025-01306-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).</p><p><strong>Methods: </strong>Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.</p><p><strong>Conclusion: </strong>Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"194"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma.\",\"authors\":\"Arif Akyildiz, Betul Gok Yavuz, Rashad Ismayilov, Muge Buyukaksoy, Sena Sozen, Joe Ramzi Eid, Rony Avritscher, Lee Sunyoung, Suayib Yalcin, Ahmed O Kaseb\",\"doi\":\"10.1007/s12029-025-01306-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).</p><p><strong>Methods: </strong>Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.</p><p><strong>Conclusion: </strong>Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.</p>\",\"PeriodicalId\":15895,\"journal\":{\"name\":\"Journal of Gastrointestinal Cancer\",\"volume\":\"56 1\",\"pages\":\"194\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12029-025-01306-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01306-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma.
Introduction: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).
Methods: Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.
Conclusion: Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.
期刊介绍：
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
